In its May 18 ruling, the U.S. Supreme Court sided with Sanofi in Amgen v. Sanofi, 598 U.S. (2023), a dispute concerning broad functional genus claims for antibodies. The Supreme.
The U.S. Patent and Trademark Office requires that patent specifications include a written description of the technology that is sought to be patented. Not just a concern for patent.